AI assistant
ABBOTT LABORATORIES — Director's Dealing 2020
Feb 25, 2020
29777_dirs_2020-02-25_4ff08f32-ebc9-4004-981a-afd30de4e7e2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2020-02-21
Reporting Person: Earnhardt Lisa D (Executive Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-02-21 | Common shares without par value | A | 18855 | — | Acquired | 75801 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-02-21 | Option (right to buy) | $87.72 | A | 114940 | Acquired | 2030-02-20 | Common shares (114940) | Direct |
Footnotes
F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,313 on February 21, 2021, 38,313 on February 21, 2022, and 38,314 on February 21, 2023.